Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001193125-26-120690
Filing Date
2026-03-24
Accepted
2026-03-24 07:10:26
Documents
93
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 10-K achv-20251231.htm   iXBRL 10-K 4372519
2 EX-10.14 achv-ex10_14.htm EX-10.14 111121
3 EX-10.32 achv-ex10_32.htm EX-10.32 71477
4 EX-21.1 achv-ex21_1.htm EX-21.1 3599
5 EX-23.1 achv-ex23_1.htm EX-23.1 3738
6 EX-31.1 achv-ex31_1.htm EX-31.1 12533
7 EX-31.2 achv-ex31_2.htm EX-31.2 15841
8 EX-32.1 achv-ex32_1.htm EX-32.1 6223
9 EX-32.2 achv-ex32_2.htm EX-32.2 6677
  Complete submission text file 0001193125-26-120690.txt   16993112

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT achv-20251231.xsd EX-101.SCH 2132407
97 EXTRACTED XBRL INSTANCE DOCUMENT achv-20251231_htm.xml XML 3428716
Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Filer) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 033-80623 | Film No.: 26784153
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)